Search research articles
Contact Us
Filters
Showing results (1-10 of 39) with videos related to
Page
of 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2017
Is Bootstrapping Sufficient for Validating a Risk Model for Selection of Participants for a Lung Cancer Screening Program?
Michael W Marcus, John K Field
Journal of Glaucoma
|
June 25, 2011
Risk factors for visual field progression in the groningen longitudinal glaucoma study: a comparison of different statistical approaches
Christiaan Wesselink, Michael W Marcus, Nomdo M Jansonius
Translational Lung Cancer Research
|
March 24, 2017
Risk assessment in relation to the detection of small pulmonary nodules
John K Field, Michael W Marcus, Matthijs Oudkerk
Oncology Reports
|
August 3, 2017
Age at menopause and hormone replacement therapy as risk factors for head and neck and oesophageal cancer (Review)
Caroline E McCarthy, John K Field, Michael W Marcus
Journal of Thoracic Disease
|
May 19, 2015
Lung cancer screening: identifying the high risk cohort
Michael W Marcus, Olaide Y Raji, John K Field
American Journal of Health Promotion : AJHP
|
October 27, 2016
Utilizing Lung Cancer Risk Prediction Models to Promote Smoking Cessation: Two Randomized Controlled Trials
Frances C Sherratt, Michael W Marcus, Jude Robinson, et al.
Oncology Letters
|
March 20, 2015
Impact of comorbidity on lung cancer mortality - a report from the Liverpool Lung Project
Michael W Marcus, Ying Chen, Stephen W Duffy, et al.
British Journal of Health Psychology
|
December 17, 2015
Perceptions towards electronic cigarettes for smoking cessation among Stop Smoking Service users
Frances C Sherratt, Lisa Newson, Michael W Marcus, et al.
Clinical Therapeutics
|
June 6, 2019
DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications: A Contemporary Experience From UK General Practice
Dionysis Spanopoulos, Michael Busse, Joanne Webb, et al.
Clinical Therapeutics
|
February 19, 2020
Corrigendum to "DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications: A Contemporary Experience From UK General Practice" [Clinical Therapeutics 41 (8) (2019) 1622-1630]
Dionysis Spanopoulos, Michael Busse, Joanne Webb, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 39) with videos related to
Sort By:
Page
of 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2017
Is Bootstrapping Sufficient for Validating a Risk Model for Selection of Participants for a Lung Cancer Screening Program?
Michael W Marcus, John K Field
Journal of Glaucoma
|
June 25, 2011
Risk factors for visual field progression in the groningen longitudinal glaucoma study: a comparison of different statistical approaches
Christiaan Wesselink, Michael W Marcus, Nomdo M Jansonius
Translational Lung Cancer Research
|
March 24, 2017
Risk assessment in relation to the detection of small pulmonary nodules
John K Field, Michael W Marcus, Matthijs Oudkerk
Oncology Reports
|
August 3, 2017
Age at menopause and hormone replacement therapy as risk factors for head and neck and oesophageal cancer (Review)
Caroline E McCarthy, John K Field, Michael W Marcus
Journal of Thoracic Disease
|
May 19, 2015
Lung cancer screening: identifying the high risk cohort
Michael W Marcus, Olaide Y Raji, John K Field
American Journal of Health Promotion : AJHP
|
October 27, 2016
Utilizing Lung Cancer Risk Prediction Models to Promote Smoking Cessation: Two Randomized Controlled Trials
Frances C Sherratt, Michael W Marcus, Jude Robinson, et al.
Oncology Letters
|
March 20, 2015
Impact of comorbidity on lung cancer mortality - a report from the Liverpool Lung Project
Michael W Marcus, Ying Chen, Stephen W Duffy, et al.
British Journal of Health Psychology
|
December 17, 2015
Perceptions towards electronic cigarettes for smoking cessation among Stop Smoking Service users
Frances C Sherratt, Lisa Newson, Michael W Marcus, et al.
Clinical Therapeutics
|
June 6, 2019
DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications: A Contemporary Experience From UK General Practice
Dionysis Spanopoulos, Michael Busse, Joanne Webb, et al.
Clinical Therapeutics
|
February 19, 2020
Corrigendum to "DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications: A Contemporary Experience From UK General Practice" [Clinical Therapeutics 41 (8) (2019) 1622-1630]
Dionysis Spanopoulos, Michael Busse, Joanne Webb, et al.
Page
of 4